The EMA (European Medicines Agency) data quality framework provides a set of guidelines and principles for ensuring high-quality data in real-world evidence (RWE) studies in the context of EU medicines regulation. The framework aims to promote the use of RWE in the assessment of medicines, and to ensure that RWE studies are conducted in a rigorous and reliable manner.

The impact of the EMA data quality framework on RWE can be significant. By promoting high-quality data collection and analysis in RWE studies, the framework can help to ensure that the results of such studies are reliable and can be used to inform regulatory decision-making. This, in turn, can facilitate the timely access of patients to new treatments and can help to improve public health outcomes.

The framework encourages the use of transparent and reproducible methods in RWE studies, which can help to ensure that the results are credible and trustworthy. The use of standardized data collection and analysis methods can also facilitate the comparison of results across different studies and settings, which can help to build a more comprehensive understanding of the safety and efficacy of medicines.

Overall, the EMA data quality framework can help to promote the use of RWE in medicines regulation and improve the quality and reliability of RWE studies. This can have a positive impact on public health by facilitating timely access to new treatments and improving the understanding of the safety and efficacy of medicines.